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Perilipin 5 (PLIN5) is a lipid droplet (LD) protein highly expressed in oxidative tissues, including the
fasted liver. However, its expression also increases in nonalcoholic fatty liver. To determine
whether PLIN5 regulates metabolic phenotypes of hepatosteatosis under nutritional excess, liver
targeted overexpression of PLIN5 was achieved using adenoviral vector (Ad-PLIN5) in male
C57BL/6J mice fed high-fat diet. Mice treated with adenovirus expressing green fluorescent pro-
tein (GFP) (Ad-GFP) served as control. Ad-PLIN5 livers increased LD in the liver section, and liquid
chromatography with tandem mass spectrometry revealed increases in lipid classes associated
with LD, including triacylglycerol, cholesterol ester, and phospholipid classes, compared with
Ad-GFP liver. Lipids commonly associated with hepatic lipotoxicity, diacylglycerol, and ceramides,
were also increased in Ad-PLIN5 liver. The expression of genes in lipid metabolism regulated by
peroxisome proliferator-activated receptor- was reduced suggestive of slower mobilization of
stored lipids in Ad-PLIN5 mice. However, the increase of hepatosteatosis by PLIN5 overexpression
did not worsen glucose homeostasis. Rather, serum insulin levels were decreased, indicating
better insulin sensitivity in Ad-PLIN5 mice. Moreover, genes associated with liver injury were
unaltered in Ad-PLIN5 steatotic liver compared with Ad-GFP control. Phosphorylation of protein
kinase B was increased in Ad-PLIN5-transduced AML12 hepatocyte despite of the promotion of
fatty acid incorporation to triacylglycerol as well. Collectively, our data indicates that the increase
in liver PLIN5 during hepatosteatosis drives further lipid accumulation but does not adversely
affect hepatic health or insulin sensitivity. (Molecular Endocrinology 29: 1414–1425, 2015)
Nonalcoholic fatty liver disease (NAFLD) is a meta-bolic disorder characterized by the accumulation of
triacylglycerol (TG) in the liver in the absence of alcohol
consumption. It affects up to 30% of the adult population
in the United States and is currently the leading cause of
chronic liver disease in the world (1). Health risks asso-
ciated with NAFLD include the potential progression to
liver cirrhosis and hepatocellular carcinoma, and the de-
velopment of insulin resistance and type 2 diabetes (2–4).
Although TG accumulation is the hallmark of NAFLD, its
metabolites rather than TG itself are considered to cause
dysregulation of insulin signaling and liver injury (5, 6).
Free fatty acids (FAs), especially saturated FA such as
palmitic and stearic acids are cytotoxic and provoke en-
doplasmic reticulum stress, oxidative stress, and inflam-
matory responses in the liver (5). The increase in diacyl-
glycerol (DG) in steatotic liver is believed to activate
protein kinase C and blunt insulin signaling (6). There-
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fore, factors that regulate storage and metabolism of TG
in the liver are likely to be critically involved in the devel-
opment of pathologies associated with NAFLD.
TG are primarily stored in lipid droplets (LDs) in hepa-
tocytes. LDs are intracellular organelles composed of a
neutral lipid core encased by a phospholipid monolayer
that is studded with proteins to orchestrate the formation,
movement, and use of stored lipids (7). Importantly, pro-
teome analysis of hepatic LDs revealed a unique enrich-
ment of multiple metabolic enzymes reflecting key roles of
hepatic LDs in the regulation of hepatic metabolism (8).
The perilipin (PLIN) family of proteins (PLIN1–PLIN5) is
the prototypical LD proteins important for the formation
of LDs (9). In mouse models of NAFLD such as diet-
induced obese mice and ob/ob mice, PLIN2, PLIN3, and
PLIN5 are increased (10–12). Both in vivo and in vitro
studies imply that all 3 PLINs are involved in TG accu-
mulation in hepatocytes. Reductions of PLIN2 prevent
TG accumulation in hepatocytes in culture (13) and in the
liver of diet-induced obese mice (14–17). Similarly,
down-regulation of PLIN3 using antisense oligonucleo-
tides improved diet-induced hepatosteatosis in mice (11).
Lastly, TG contents were decreased in primary mouse
hepatocytes after PLIN5 reduction (18) and in the liver
from whole body PLIN5-deficient mice (12). The reduc-
tion of hepatosteatosis was associated with the improve-
ment in insulin sensitivity when PLIN2 and PLIN3 were
down-regulated in mice on high-fat diet (HFD) (11, 16,
17). The improvement in hepatic insulin sensitivity was
also noted in whole body PLIN5-deficient mice but were
fed regular rodent chow (NC) (19). Collectively, LD for-
mation in the liver seems to precipitate insulin resistance.
However, there is also evidence indicating that the pre-
vention of LD formation in the liver accelerates hepatic
injury under excessive nutritional load. Microarray anal-
ysis of the liver from HFD-fed mice treated with antisense
oligonucleotides against PLIN2 showed the increase in
markers of hepatic proliferation (Afp and H19) and ex-
tracellular matrix remodeling (20). Markers of inflamma-
tion and oxidative stress were also increased in the liver of
PLIN5-deficient mice on HFD (12). To add complexity,
hepatic overexpression of PLIN2 in regular chow-fed
mice caused hepatosteatosis with improvement in insulin
sensitivity (21), indicating that the interplay between nu-
tritional environment and PLINs may determine how TG
accumulation modifies insulin signaling and hepatic inju-
ries in NAFLD. To understand the nature of interactions
between PLINs and nutritional environment, knowledge
regarding how different PLINs regulate accumulation of
TG in the liver and hepatocyte health in vivo will be
important. Although all 3 PLINs (PLIN2, PLIN3, and
PLIN5) seem to participate in TG accumulation in the
liver, each PLIN potentially has distinct roles due to
unique structural characteristics. PLIN5 interacts with
key lipases adipose triglyceride lipase (ATGL) and its co-
lipase comparative gene identification-58 (CGI-58) (22–
24) and may be linked to mitochondria to better facilitate
FA oxidation (25). Notably, PLIN5 knockdown in pri-
mary mouse hepatocytes increased lipolysis and FA oxi-
dation, whereas the knockdown of PLIN2 and PLIN3 in
AML12 hepatocyte cell line did not affect lipolysis (18,
26).
Here, PLIN5 was overexpressed in the liver of mice on
HFD via adenovirus to determine how PLIN5 will affect
markers of glucose homeostasis and hepatic injuries
along with hepatic lipid profiles. We used high-resolu-
tion accurate mass spectrometry to identify lipid spe-
cies differentially regulated by PLIN5 overexpression




Experiments were performed in accordance with the Institu-
tional Animal Care and Use Committee guidelines of Eastern
Virginia Medical School. Three-month-old male C57Bl/6J (Bl6)
(The Jackson Laboratory) were housed in 12-hour light, 12-
hour dark cycle at 22°C and fed HFD containing 45 kcal% fat
(D124551; Research Diets) or NC (Harlan 2018) ad libitum for
6 weeks (regular chow and HFD) or 16 weeks (HFD only).
Thereafter, type 5 adenoviruses expressing green fluorescent
protein (GFP) (Ad-GFP) or mouse PLIN5 (Ad-PLIN5) under
cytomegalovirus promoter, all from Vector Biolabs, were deliv-
ered through tail vein injection at 1  109 plaque forming units
per mouse. Mice continued to consume HFD throughout the
study up until harvest. Ten to fourteen days after adenovirus
injection, mice fed ad libitum were euthanized by carbon diox-
ide asphyxiation in late morning. Cardiac blood was collected
for serum analyses. Left lateral lobe of the liver was fixed in 10%
formalin for histological analyses. The rest of the liver were snap
frozen in liquid nitrogen upon harvest and stored at 80°C until
analyses.
Glucose homeostasis
For glucose tolerance test (GTT), mice fasted overnight re-
ceived glucose ip at 1-mg/g body weight (HFD) or 1.5-mg/g
body weight (NC). For insulin tolerance test (ITT), mice fasted
for 4 hours in the morning received insulin lispro (Eli Lilly) ip at
1.0-mIU/g body weight (HFD) or 0.75-mIU/g body weight
(NC). Tail blood glucose was measured at indicated times using
a One Touch Ultra hand-held glucometer (LifeScan, Inc).
Colorimetric assays
Cardiac blood collected at harvest was centrifuged at 7000
revolutions per minute for 10 minutes at room temperature to
obtain serum. TG (Stanbio Laboratories), -hydroxybutyrate
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(Stanbio), nonesterified FA (Wako Chemicals), and mouse in-
sulin (Mercodia) were measured in the serum according to man-
ufacturers’ instructions. Liver TG were measured using an
aforementioned TG colorimetric assay after Folch extraction as
we published and corrected for protein contents (27).
Cell culture and adenovirus transduction
AML12 hepatocyte cells obtained from American Type Cul-
ture Collection and grown in 50/50 DMEM/Ham’s F12 media
supplemented with 10% fetal bovine serum; insulin, transferrin,
and selenium (Gibco); and 40-ng/mL dexamethasone (Sigma)
were transduced in suspension at 80 plaque forming units per
cell of Ad-PLIN5 or Ad-GFP for 1 hour in serum-free growth
medium, and then cultured overnight in 10% fetal bovine serum
growth medium at 37°C in 5% CO2. For labeling studies, trans-
duced cells were incubated with 1.2-Ci/mL [3H]oleic acid (OA)
(specific activity 10 mCi/mol; NEN) and the 16- to 18-hour
incorporation of [3H]OA to the TG fraction was determined as
in Ref. 28. Lipolysis in response to cAMP was determined as the
reduction of [3H]OA-labeled TG in AML12 cells treated with or
without 1 mmol/L 8-bromoadenosine 3,5-cyclic monophos-
phate (Sigma) in the presence of 9.5 mol/L triacsin C (Enzo Life
Sciences) to prevent reincorporation of [3H]OA to TG. Data
were normalized to cellular protein contents.
mRNA and quantitative PCR
Total RNA from liver tissues (50–100 mg) were prepared
using QIAGEN RNeasy kit (QIAGEN) according to the manu-
facture’s protocol and reverse transcribed with iScript (Bio-
Rad). Gene expressions were assessed using ABI TaqMan com-
mercial primers (Applied Biosystems) and results were
expressed taking -actin as an internal standard.
Western blotting
Tissues were homogenized in lysis buffer with the addition of
protease and phosphatase inhibitor cocktails (both from Sigma)
as published (15). Western blottings were performed using
20–40 g/lane of protein measured by Bio-Rad DC Protein
Assay (Bio-Rad), and signals were visualized by chemilumines-
cence. Densitometric analyses were performed with ImageJ us-
ing glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as an
internal control. Primary antibodies were guinea pig anti-PLIN5
(Progen Biotechnik) at 1:1000 and guinea pig anti-PLIN2
(Fitzgerald) at 1:1000. Rabbit anti-GAPDH, rabbit antiphos-
phorylated Akt S473, and mouse anti-Akt (pan) were all diluted
at 1:1000 and all from Cell Signaling Technology. Secondary
antibodies were horseradish peroxidase-conjugated goat anti-
guinea pig-IgG and horseradish peroxidase-conjugated goat an-
tirabbit-IgG (Santa Cruz Biotechnology, Inc) both at 1:5000.
Histological analyses of the liver
Paraffin-embedded liver sections were incubated with pri-
mary antibodies followed by visualization using fluorescent sec-
ondary antibodies as previously published (15) except that
slides were incubated with Sudan Black B (MP Biomedicals) at
0.1% for PLIN5 and 0.4% for PLIN2 for 25 minutes after the
incubation with secondary antibodies to reduce autofluores-
cence (29). Primary antibodies were guinea pig anti-PLIN5 (Pro-
gen) at 1:200 and guinea pig anti-PLIN2 at 1:800 (Fitzgerald).
Secondary antibodies were Cyanine3 antiguinea pig antibodies
at 1:1000 from Jackson ImmunoResearch. Nuclei were visual-
ized with 1-g/mL 4,6-diamidino-2-phenylindole (Life Tech-
nologies). Images of liver sections were recorded with AxioOb-
server Z.1 fluorescent microscope (Carl Zeiss) or a confocal
microscope (LSM510; Carl Zeiss).
Determination of liver lipids by liquid
chromatography with tandem mass spectrometry
(LC-MS/MS)
Lipids were extracted from 400 mg of the same area of the
liver across the samples as described (28). A total of 10M lipid
standards to include a monoacylglycerol, DG, and TG mix (Su-
pelco), palmitic acid, and cholesterol ester (CholE) (both from
Sigma) was spiked into each tissue lysate before lipid extraction.
Samples were analyzed on the Q-Exactive Orbitrap platform
(Thermo Fisher Scientific) via LC-MS/MS (30, 31) between 70K
and 140K resolutions for the Full MS and up to 35K resolution
for product ion scan data (MS2). Product ion spectrum at 35K
was obtained using higher collision dissociation fragmentation
for the 5 most abundant ions observed from the Full MS spec-
trum. The overfill ratio for the Orbitrap was setup at 2e3 ions
that is also considered as the threshold for the dynamic range of
the spectrum below which no product ion MS2 ions were col-
lected for lipid identification. Instrument settings are described
in detail within the Supplemental Methods.
Peak analysis was performed by Lipid Search algorithm
(Mitsubishi Knowledge Industry) that performs peak detection
with raw files, MSn, and precursor ion accurate masses (28).
Lipid Search algorithm identifies lipids by comparing the raw
file of MS2 with a comprehensive database of over 106 lipid
species. The identification of each product ion is ranked by mass
tolerance, matched to a fragmentation library and predicted
retention time to determine the molecular structure of the pre-
cursor ion. For the dataset, the mass tolerance was set to 5 parts
per million for the precursor mass. Relative quantitation for the
analytes is performed using the precursor ion data based on the
high-resolution accurate mass information. MS/MS spectra
were manually inspected and species assigned based on known
lipid fragmentation. Spectra corresponding to the peak apex of
each extracted ion chromatogram were examined for relation-
ships between adducts, isotopes and dimers using accurate mass
measurements. Related ions with similar retention times were
grouped together into a component table represented by the
largest adduct peak.
For lipid quantification, identified species are aligned across
Ad-PLIN5 and Ad-GFP liver groups and the integrated precur-
sor extracted ion chromatograms are calculated to compare area
differences for the individual lipid species. LC-MS data were
corrected for the mean background obtained from the average
of 2 blank solvent injections. Livers from 3 mice per group
(biological triplicates) were analyzed with technical duplicate
for Ad-PLIN5 group yielding 3 values for Ad-GFP and 6 values
for Ad-PLIN5 groups. For the 6 values in Ad-PLIN5, outliers
defined as outside of median-(3 median absolute deviation)
and median(3 median absolute deviation) were removed.
The statistical comparison of individual lipid species between
Ad-GFP and Ad-PLIN5 was performed using Wilcoxon rank
test. The abundance of the lipid class was determined as the sum
of peak area of lipid species that belong to a lipid class. For
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Ad-PLIN5 group, the average of technical duplicates was used
to represent the liver from each mouse.
Statistics
Data are presented as mean  SEM. Differences of numeric
parameters between 2 groups were assessed with Student’s t
tests or Mann-Whitney test, and those for multiple group com-
parisons were assessed with one-way ANOVA (Tukey post hoc
test). P  .05 was considered significant.
Results
Adenovirus-mediated overexpression of PLIN5
promotes hepatic TG and LD accumulations in Bl6
mice on HFD
In mouse models of NAFLD such as diet-induced obese
mice and ob/ob mice, PLIN5 is reported to be increased
(Supplemental Figure 1A) (12, 26). To determine the con-
sequence of PLIN5 overexpression in the liver in the set-
ting of HFD, adenoviruses expressing Plin5 (Ad-PLIN5)
or control (Ad-GFP) were injected into the tail vein of
male Bl6 mice fed HFD for 6 weeks before injection. Two
weeks after adenovirus administration, livers from Ad-
PLIN5 mice on the HFD showed significant increases in
Plin5 mRNA levels but did not show changes in the he-
patic expressions of other members of the Plin family,
including Plin2 (Figure 1A). Western blotting of the liver
showed PLIN5 protein expression was successfully in-
creased to 2-fold in mice treated with Ad-PLIN5 over
Ad-GFP (Figure 1B). In contrast to the heart (32) and
pancreatic islets (28) where the induction of PLIN5 pro-
moted an increase in PLIN2 protein without changes in
Plin2 mRNA expression, hepatic PLIN2 protein did not
increase after the overexpression of hepatic PLIN5 in
mice with diet-induced hepatosteatosis (Figure 1C). In
agreement with in vitro data in which PLIN5 expression
increased cellular TG contents in AML12 cells (18), in
vivo overexpression of PLIN5 in the liver significantly
increased hepatic TG contents in Ad-PLIN5 mice (Figure
2A). Hematoxylin eosin-stained liver sections revealed
that 6 weeks of HFD resulted in steatosis in both Ad-GFP
and Ad-PLIN5 mice but with more prominent and diffuse
appearance of large LD in Ad-PLIN5 mice (Supplemental
Figure 1B). In agreement with hematoxylin eosin, PLIN2
staining showed large PLIN2-coated LDs were quite
abundant in the livers of Ad-PLIN5 mice compared with
Ad-GFP mice (Figure 2B). Immunofluorescence using
PLIN5 antibody showed ring like staining typical of LDs
in Ad-PLIN5 liver, whereas such staining was rarely de-
tected in Ad-GFP liver (Figure 2B) within the sensitivity of
antibody currently available for immunofluorescence.
PLIN5-coated LD was not detected in hepatic stellate cells
nor vimentin positive cells, including Kupffer cells, leuko-
cytes, and endothelia cells (Supplemental Figure 1, C and
D). Taken together, these data implies that PLIN5 over-
expression in the liver exacerbates hepatosteatosis bio-
chemically and histologically in mice on HFD.
Despite its location on the surface of LD, the down-
regulation of PLIN5 in the liver and cultured cells affects
the expressions of a wide range of genes in lipid metabo-
lism (12, 18). In the current study, the overexpression of
PLIN5 in HFD mice showed significant reductions of
genes involved in lipolysis (Pnpla2 and Lipe) and FA ox-
idation (Cpt1 and Acot2, P  .05 vs Ad-GFP) (Figure
2C). There were also trends for the reduction in genes for
lipogenesis (Dgat1 and Dgat2) in Ad-PLIN5 mice (P 
.05 vs Ad-GFP) (Figure 2C). No significant differences in
FA synthesis-related genes (Fasn and Scd1) were mea-
sured with PLIN5 overexpression compared with Ad-
Figure 1. Adenovirus-mediated expression of PLIN5 in liver of mice
on HFD. A, Quantitative PCR of Plin1-Plin5 levels in livers of Ad-GFP-
and Ad-PLIN5-treated mice on 6 week of HFD presented taking the
average levels from Ad-GFP mice as 100% and normalized using -
actin as an internal control. ND, not detected. Data are mean  SEM;
n  5–6 per group; *, P  .05. B and C, Western blotting of PLIN5 (B)
and PLIN2 (C) in Ad-GFP and Ad-PLIN5 livers using GAPDH as an
internal control. Representative pictures on the left and band density
of PLIN5 (B) and PLIN2 (C) taking the average expression levels from
Ad-GFP-treated mice as 1 on the right. Data are mean  SEM; n 
5–6 per group; **, P  .01.
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GFP control. The common transcriptional regulator of
these genes for lipid metabolism, peroxisome prolifera-
tor-activated receptor (PPAR)- (Ppara) was previously
shown to be down-regulated when PLIN5 was overex-
pressed in the cardiac muscle (32, 33). Comparably, we
observed a significant reduction in hepatic Ppara expres-
sion in Ad-PLIN5 mice that may explain the decreased
expressions of other hepatic lipid enzymes (Figure 2C).
Overall hepatic PLIN5 overexpression results in the re-
duction in PPAR- and PPAR--regulated genes, the op-
posite of changes observed in PLIN5-deficient liver (12).
LC-MS/MS reveals changes in the lipidome of liver
overexpressing PLIN5
To gain a more detailed characterization of lipidomes in
Ad-PLIN5 liver, we performed unbiased, shotgun compar-
ison of lipids between the livers of Ad-GFP- and Ad-PLIN5-
treated Bl6 mice on HFD using high resolution Q-Exactive
LC-MS/MS. Using the condition previously described (30,
31), we identified phosphatidylcholine (PC), phosphatidyle-
thanolamine (PE), phosphatidylser-
ine, phosphatidylglycerol, phosphati-
dylinositol, ceramides (Cers), CholE,
TG, and DG in lipids extracted from
the livers. In Figure 3A, the represen-
tative total ion chromatogram depicts
mass spectral peaks across all m/z in
positive ion mode. Neutral lipids
commonly enriched in LDs, including
TG, DG, and CholE (34), were accu-
rately detected with the Q-Exactive.
The abundance of these 3 lipid classes
was significantly increased in the liver
of Ad-PLIN5 mice with the most
prominent rise in DG at the fold in-
crease of 2.6-fold compared with Ad-
GFP control (Figure 3B). PC and PE,
phospholipids abundantly found at
the surface of LDs (35), were also de-
tected in our assays with the signifi-
cant increase for PE in PLIN5 overex-
pressing liver (Figure 3C). Among
other less abundant phospholipids,
phosphatidylserine and phosphatidyl-
inositol were substantially increased
in the Ad-PLIN5 liver (Figure 3C). In
addition, Cer showed a trend of in-
crease in the Ad-PLIN5 liver (Figure
3D), indicating that PLIN5 overex-
pression drives the increase in a wide
range of lipid classes.
We identified 609 TG species
with the sum of 3 FA chains from
C34 to C74 in both Ad-GFP and Ad-PLIN5 livers, of
which 50 species were increased more than 2-fold and 8
species were reduced to less than 0.5-fold in Ad-PLIN5
liver (P  .05) (Supplemental Tables 1 and 2). The 100
TG species most abundant in Ad-GFP liver (Figure 4A)
represented 76% of total TG in abundance for both Ad-
GFP and Ad-PLIN5 livers. These TG species mostly con-
sisted of C50 to C56, which is in agreement with total
carbon distribution previously reported in the mouse liv-
ers (34). Interestingly, Ad-PLIN5 liver contained more
saturated FA compared with Ad-GFP liver when the ex-
tent of unsaturation was compared in individual FA chain
length between C14 and C18 (Spearman r  0.80, P 
.01) (Figure 4B).
We identified 154 DG species that ranged from C24 to
C56, of which 92 species were increased more than 2-fold
and 2 DG species were reduced to less than 0.5-fold in
Ad-PLIN5 liver reflecting the significant rise in total DG
in Ad-PLIN5 liver compared with Ad-GFP liver (P  .05)
Figure 2. Change in lipids and LD in HFD mice treated with Ad-PLIN5. A, Hepatic TG
quantitated in livers of Ad-GFP- and Ad-PLIN5-treated mice after 6 week of HFD. Data are
mean  SEM; n  5–6 per group; *, P  .05. B, Liver sections from Ad-GFP (top row)- and Ad-
PLIN5 (bottom row)-treated mice immunostained with PLIN2 and immunostained with PLIN5
along with negative control (no primary antibodies). Scale bar, 10 m. C, Quantitative PCR
determined the expression of genes involved in major lipid metabolic pathways in livers of Ad-
PLIN5 male mice on HFD for 6 weeks. Levels are presented taking the levels of Ad-GFP on the
corresponding duration of HFD as 100%. Expression levels were normalized using -actin as an
internal control. Data are mean  SEM; n  5–6; *, P  .05; **, P  .01. Pnpla2, ATGL; Lipe,
hormone-sensitive lipase (aka HSL); Dgat1 and Dgat2, DG acyltransferases 1 and 2; Cpt1a,
carnitine palmitoyltransferase 1; Fasn, FA synthase; Scd1, stearoyl-CoA desaturase-1; Acot2,
acyl-CoA thioesterase 2; Ppargc1a, PPAR- coactivator 1.
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(Supplemental Tables 3 and 4). Most DG belonged to
C34 and C38 for both groups followed by C36 and C40
(Supplemental Figure 2). Five CholE species were identi-
fied in the liver, of which CholE(20:4) and CholE(22:6)
contributed to the increase in total CholE in Ad-PLIN5-
treated liver compared with Ad-GFP control liver (Sup-
plemental Figure 3A). Our lipidomics also identified 31
Cer species present in both Ad-PLIN5 and Ad-GFP liver
with many of them significantly increased in Ad-PLIN5
liver compared with Ad-GFP control. Cers with d18:01
backbone was most abundant. However, we also identi-
fied those with d18:2 and d18:0
(Supplemental Figure 3B). Cer(d18:
1/16:0) has been implicated as a con-
tributor to insulin resistance in the
liver (36, 37) and was also the most
prominent Cer present in both livers
in our study. At the same time, very
long chain Cers (C22 to C24) that
may have the opposite effect of C16
Cers (37) were highly abundant and
significantly increased in Ad-PLIN5
liver (Supplemental Figure 3B).
We identified 120 PC species and
130 PE species (Supplemental Fig-
ures 4 and 5A). Although total PC
did not show statistically significant
alterations, many PC species were
increased in Ad-PLIN5 liver com-
pared with Ad-GFP liver leaving
only 5 species of PC to be signifi-
cantly reduced to less than 0.5-fold
in Ad-PLIN5 liver (Supplemental
Table 5). PC (16:0/18:1) previously
identified as a ligand for PPAR-
(38), was the most prominent PC
species and significantly increased in
Ad-PLIN5 liver (Supplemental Fig-
ure 4). Collectively, Ad-PLIN5 ex-
pression in the liver resulted in the
increase of a broad spectrum of lip-
ids both in terms of type of lipids and
chain compositions within each
lipid classes.
However, the increase of lipids
mediated by PLIN5 overexpression
had little impact on markers associ-
ated with liver injury that were pre-
viously noted to be increased in the
liver of mice on HFD compared with
regular chow-fed mice (20). In Fig-
ure 4C, quantitative PCR revealed
the Colla2 was significantly reduced in the livers of Ad-
PLIN5 mice on 6-week HFD (P  .05 vs Ad-GFP), and
there were no major changes in genes associated with
hepatic proliferation in response to hepatic injury (Afp
and H19). In Supplemental Figure 5B, adenovirus treat-
ment itself did not seem to increase these genes in the liver.
In comparison, the reduction of PLIN2 or PLIN5 in the
livers of HFD mice was reported to up-regulate genes of
liver injuries (12, 20). Thus, PLIN5 seems to aid in the
expansion of the hepatic neutral lipid pool without acti-
vating genes associated with steatohepatitis.
Figure 3. Changes in the hepatic lipidome of HFD mice treated with Ad-PLIN5. Lipids extracted
from the livers of 6 weeks HFD mice treated with Ad-GFP or Ad-PLIN5 and harvested at fed ad
libitum in late morning as in Materials and Methods were analyzed by Q-Exactive LC-MS/MS as in
Materials and Methods. A, The representative total ion chromatogram of lipids in Ad-GFP liver in
full MS. B–D, Relative intensity of neutral lipids (B), phospholipids (C), and Cers (D) determined as
in Materials and Methods was compared between liver from Ad-GFP and Ad-PLIN5 mice. PG,
phosphatidylglycerol; PS, phosphatidylserine; PI, phosphatidylinositol. Data are mean  SEM; n 
3; *, P  .05; **, P  .01; n.s., not significant.
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Figure 4. Profiles of the TG lipid class in the livers of HFD mice overexpressing PLIN5. A, Relative abundance (peak area) of the 100 most
abundant TG species identified in the liver of Ad-GFP (white)- and Ad-PLIN5 (black)-treated mice (6-week HFD). TGs are grouped based on their
total number of carbons (c) and unsaturation (number of double bonds). Data are mean  SEM; n  3; *, P  .05. B, Correlation between the
unsaturation of C14 to C18 fatty acyl chains expressed as the number of double bonds/total carbon and abundance of fatty acyl chains expressed
as an area ratio in Ad-PLIN5 over Ad-GFP liver of the TG species as appeared in A. C, Quantitative PCR determined the expression of genes
involved in liver injury in livers of Ad-PLIN5 male mice fed HFD (6-week HFD). Levels are presented taking the levels of Ad-GFP on the
corresponding duration of HFD as 100%. Expression levels were normalized using -actin as an internal control. Data are mean  SEM; n  5–6;
*, P  .05; **, P  .01. Afp, -fetoprotein (AFP); Col1a2, collagen 1(II chain); H19, imprinted maternally expressed transcript (nonprotein coding).
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Up-regulation of hepatic PLIN5 does not accelerate
insulin resistance in mice with steatotic liver
We then evaluated the effect of hepatic PLIN5 overex-
pression on whole body glucose homeostasis. Despite the
increase in liver TG, GTT (Figure 5A) and ITT (Figure 5B)
revealed no impairment in glucose or insulin tolerance in
AD-PLIN5 mice compared with Ad-GFP mice on 6-week
HFD. In addition, we tested glucose and insulin tolerance
Figure 5. Glucose homeostasis of short- and long-term HFD mice treated with Ad-PLIN5. A–D, Mice were placed on a 6- or 16-week HFD, then
treated with Ad-GFP (closed line) and Ad-PLIN5 (dashed line). Intraperitoneal glucose tolerance (A and C) and insulin tolerance (B and D) were
evaluated in mice on the separate HFD time plans. Area under the curve (AUC) between time 0 and 60 minutes. E–G, Body weight (E), glucose in
late morning fed ad libitum (F), and serum insulin (G) measured in Ad-GFP- and Ad-PLIN5-treated male C56BL/6J mice on NC, and 6- or 16-week
HFD taken at harvest. Data are mean  SEM; n  3–6; *, P  .05; **, P  .01. H, Overnight incorporation of [3H]OAs into triglycerides (TG) in
AML12 cells transduced with Ad-PLIN5 (PLIN5) and nontransduced cells (Cont). Data are mean  SEM; n  4; ***, P  .001. I, Representative
Western blotting of phosphorylated protein kinase B (pAkt S473) and total protein kinase B (totAkt) in AML12 cells transduced with Ad-PLIN5 and
Ad-GFP. Band density expressed taking the average expression levels of from Ad-GFP as 1 relative to totAkt.
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when PLIN5 were overexpressed in the liver of mice on a
longer term of HFD (16 weeks) and those maintained on
NC for 6 weeks (Supplemental Figure 6, A and B). Glucose
and insulin tolerance were similar between Ad-GFP and
Ad-PLIN5 nice on NC (Supplemental Figure 6, C and D). In
Figure 5C, the overexpression of PLIN5 in the liver did not
lead to significant changes in glucose tolerance in 16-week
HFD mice. However, there was a trend for the improvement
in the insulin tolerance of 16-week HFD Ad-PLIN5 mice
compared with Ad-GFP control (P  .06 for area under the
curve, time 0–60 minutes) (Figure 5D). Characterization of
metabolic parameters, including body weight, blood glu-
cose, serum TG, serum -hydroxybutyrate, and serum
nonesterified FA levels, showed no differences between Ad-
PLIN5 and Ad-GFP mice on either NC, short or long-term
HFD, again indicating relatively quiescent expansion of he-
patic lipid pools driven by PLIN5 expression in the liver
(Figure 5, E and F, and Supplemental Figure 6, E and F).
Notably, the incremental rise in weight and serum insulin
levels without significant changes in blood glucose in Ad-
GFP mice on NC, short- and long-term HFD confirm that
adenovirus administration preserves the widely accepted
progression of insulin resistance in Bl6 on HFD (39). His-
tology (Supplemental Figure 1A) and liver TG contents
(Supplemental Figure 6G) also indicate that hepatosteatosis
is present in Ad-GFP mice on HFD. Interestingly, the liver
targeted overexpression of PLIN5 prevented the progressive
rise of serum insulin seen in AD-GFP mice. Serum insulin
levels in 16-week HFD mice were clearly lower compared
with Ad-GFP control mice (Figure 5G), which agrees with
the trend of the improvement in ITT (Figure 5D). Collec-
tively, the overexpression of hepatic PLIN5 in the setting of
diet-induced hepatosteatosis did not promote insulin resis-
tance in spite of increased liver TG and LD (Figure 2); rather
overexpression of PLIN5 was associated with reduced se-
rum insulin levels implicating an improvement in insulin
resistance.
To address the potential implication of PLIN5 expres-
sion in hepatic insulin sensitivity, murine hepatocyte cell
line AML12 was transduced with Ad-PLIN5. [3H]OA
labeling confirmed that Ad-PLIN5 promotes incorpora-
tion of FA into TG (Figure 5H) without a change in cel-
lular uptake of [3H]OA (Supplemental Figure 6H). In this
setting, Ad-PLIN5-transduced AML12 cells grown in cul-
ture medium as in Materials and Methods showed higher
phosphorylation of protein kinase B (pAkt) compared
with control cells (Figure 5I). Taken together, the overex-
pression of PLIN5 in a hepatocyte cell line increased TG
formation but enhanced a parameter of insulin signaling.
Discussion
PLIN5 is increased along with PLIN2 in fat cakes of the
liver from mice on HFD (26), indicating that PLIN5 is an
important constituent of LDs in diet-induced hepatoste-
atosis. Here, we demonstrated that adenovirus-mediated
overexpression of PLIN5 in the liver was sufficient to
drive further LD formation and alter lipid profiles in the
liver of Bl6 on HFD. Ad-PLIN5 mice on HFD showed an
up-regulation in both the size and number of hepatic LD
and the increase in hepatic TG, CholE, and DG deter-
mined by LC-MS/MS. However, the increase in hepatic
LD driven by PLIN5 overexpression by adenovirus did
not impair glucose homeostasis at least within the time
frame we observed. Rather, serum insulin levels were re-
duced in Ad-PLIN5 mice, indicating improvement in in-
sulin sensitivity. Also, there were no increases in hepato-
cyte proliferation markers, or collagen. Thus, the
expression of PLIN5 in the setting of HFD in the liver
expands hepatic lipid pools without compromising health
and insulin sensitivity of the liver.
One potential mechanism responsible for the increase
in the TG in Ad-PLIN5 liver is the prevention of lipolysis
by PLIN5. Interestingly, the increase of TG in Ad-PLIN5
liver was not associated with the rise in PLIN2 protein
indicating that PLIN5 being overexpressed might replace
PLIN2 in the coating of LD and support the increase in
TG. PLIN5 but not PLIN2 has been shown to interact
with ATGL and colipase CGI-58, 2 proteins that play
regulatory roles in lipolysis in wide ranges of tissue (40).
The reduction of CGI-58 in the liver by antisense oligo-
nucleotides and liver specific deletion of ATGL both re-
sulted in hepatosteatosis, indicating that they are key reg-
ulators of lipolysis in the liver (41, 42). The interaction of
PLIN5 with ATGL and CGI-58 is believed to hamper
lipolysis in the liver environment at least in a basal state,
as the down-regulation of PLIN5 in AML12 cells and
hepatocytes increased lipolysis (12, 18). Conversely, the
overexpression of PLIN5 in AML12 cells reduced basal
lipolysis (24). However, PLIN5 increases lipolysis in a
cAMP dependent manner in AML12 cells, COS 7cells,
and MIN6 -cell lines (Supplemental Figure 6I) (24, 28,
43). To determine the contribution of lipolysis in the ex-
acerbation of hepatosteatosis by Ad-PLIN5, a future
study should address how HFD affects phosphorylation
status of PLIN5 in vivo and its interaction with ATGL and
CGI-58 in the liver.
In addition to the direct interaction with ATGL and
CGI-58, PLIN5 may reduce lipolysis through the regula-
tion of gene expression. The reduction in both pnpla2
(ATGL) and lipe expression was noted in Ad-PLIN5 liver.
In contrast, genes for FA synthesis (Fasn) and TG synthe-
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sis (Dgat1 and Dgat2) were unchanged or reduced imply-
ing that slowing in TG use rather than increased synthesis
plays the major role in LD accumulation by PLIN5. The
change in genes involved in lipid metabolism we observed
in Ad-PLIN5 liver is similar to those seen when PLIN5
was overexpressed in skeletal muscle and heart (32, 33,
44), and is summarized as the reduction in PPAR- target
genes. Of note, the data from ATGL knockout mice indi-
cates that lipolysis by ATGL produces signals that regu-
late PPAR- activity (45, 46). Considering that PLIN5
affects the rate of lipolysis in cells, overexpression of
PLIN5 in the liver may regulate PPAR- activity through
the alteration in lipolytic signals. Interestingly, unbiased
lipidomics of the liver, we performed in the current study
showed PC (16:0/18:1) that is shown to serve as a ligand
for PPAR- (38) is increased with Ad-PLIN5 overexpres-
sion in the liver leaving the nature of signals modulating
PPAR- target genes for future determination.
Dissociation of hepatosteatosis and insulin resistance
was previously seen in several models. Deficiency of his-
tone deacetylase 3 in the liver improved insulin sensitivity
despite marked hepatosteatosis (21). This improvement
in insulin sensitivity did not require the change in insulin
signaling but was mediated by shifting metabolic sub-
strates from gluconeogenesis to lipid storage in PLIN2-
coated LD. Actually, adenovirus-mediated overexpres-
sion of PLIN2 in the liver was sufficient to improve insulin
sensitivity (21). Another potential mechanism is the re-
duction of lipotoxic metabolites. The CGI-58 down-reg-
ulation in the liver by antisense oligonucleotides pre-
vented glucose intolerance in mice on HFD despite the
increase in hepatosteatosis and higher DG contents.
However, the DG accumulation under CGI-58 reduction
was limited to LD/endoplasmic reticulum fraction,
whereas DG in the plasma membrane was reduced result-
ing in lower activation of protein kinase C, one of the
molecules considered to be responsible for the impair-
ment in insulin signaling in response to hepatosteatosis
(47). In addition to favorable effects on insulin sensitivity
implied in the current study, PLIN5 may play an impor-
tant cytoprotective role in cells under nutritional stress.
The liver and heart from PLIN5-deficient mice show in-
creases in oxidative stress (12, 48). Thus, PLIN5 may aid
in the spatial distribution of FA through its incorporation
to LDs while reducing release of lipid metabolites through
the down-regulation of PPAR- target genes. The rela-
tively benign nature of lipid accumulation driven by
PLIN5 up-regulation was also noted in heart and skeletal
muscle (32, 44).
Q-Exactive LC-MS/MS revealed that up-regulation of
lipids by PLIN5 overexpression in the liver is not limited
to TG but includes DG, CholE, and phospholipids as well.
Indeed, the fold increase in DG was higher than that of
TG, implying that LDs in Ad-PLIN5 liver is enriched with
DG. Considering that the expression of the final enzymes
responsible for TG synthesis (Dgat1 and Dgat2) was
lower in Ad-PLIN5 liver, this increase may reflect the
reduced conversion of DG to TG, which was also seen in
aforementioned hepatosteatosis due to CGI-58 down-
regulation (47). The increase in phospholipids is likely
critical to support expansion of LD as it serves as a sur-
factant to prevent coalescence of LD (49). DG may also
support LD biogenesis through its interaction with pro-
teins and phospholipids (50). It is of interest to note that
the increase in DG and PC was also noted in LDs isolated
from hepatocytes of mice after fasting and HFD, 2 con-
ditions that are known to increase PLIN5 expression in
the liver (34).
Although PLIN5 seems to drive proportional increase
in many of lipid species we detected in the liver (Figure 4
and Supplemental Figures 1–4), we observed a couple of
unique alterations in FA chain characteristics with PLIN5
overexpression. For TG, saturation tends to be higher in
C14 to C18 FA chains in Ad-PLIN5 liver compared with
control (Figure 4B). The increase in CholE was mostly
driven by those with FA with long chains. It requires
further studies to define whether difference in chain
length and saturation of these neutral lipids affects for-
mation and mobilization of LD, generation of lipid de-
rived metabolites, and hepatocyte health.
Adenovirus-mediated gene transfer is widely used to
modulate the expression of genes in the liver and known
to primarily transduce hepatocytes (51–55). However,
the method has limitations that adenovirus will be cleared
by host immune cells and will not sustain the transduc-
tion. Thus, our observation is limited to short term (2 weeks)
effects of PLIN5 overexpression in the liver. This might
have reduced sensitivity to detect some of changes such as
GTT and ITT. Future studies will require approaches
such as transgenic mice or transduction by adeno-associ-
ated virus to achieve long-term expression of PLIN5 by
gene transfer. Also, the increase in baseline inflammation
due to host immune cells could modify phenotypes ob-
served using adenovirus. Thus, the interpretation of pa-
rameters such as liver injury and inflammation should
take this limitation into account. Despite these limita-
tions, we demonstrated that Ad-GFP-treated mice pro-
gressively increase weight, serum insulin, and liver steato-
sis supporting that metabolic hallmarks associated with
HFD are maintained after adenovirus transduction and
that these mice serve as appropriate controls for the cur-
rent study.
In summary, adenovirus-mediated overexpression of
PLIN5 in the liver resulted in expansion of liver lipids that
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is not limited to TG but include DG, CholE, phospholip-
ids, and part of Cer species, without apparent impairment
in insulin sensitivity or activation of markers associated
with steatohepatitis.
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